Ascendis Health said on Friday that its subsidiary, Remedica, had delivered revenue growth of 18% in the year to November driven by the launch of new products.
It said on Friday that Remedica “forms a material part of the company’s de-gearing strategy and continues to perform well and in line with management’s expectations”. Sardi said potential buyers may have sought to take advantage of weakness in the group’s balance sheet to extract value, but Ascendis was intent on getting a fair deal.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Market data — December 30 2019Market data including bonds, unit trusts and fuel prices
Source: BDliveSA - 🏆 12. / 63 Read more »